Paper Details

  1. Home
  2. Paper Details

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.

Author: BaldiniAlessandra, CoateBruce, DeMasiRalph, LuoDonghan, MrusJoseph, WitekJames, ZeuzemStefan

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Anemia is a common side effect of telaprevir-based triple therapy for genotype 1 hepatitis C. Identifying patients at risk for anemia could help in evaluating their suitability for this therapy, as well as determining the frequency of monitoring and treatment management.
Paper Details　
Original Abstract of the Article :
Anemia is a common adverse event associated with telaprevir-based triple therapy of chronic, genotype 1 hepatitis C. Identification of patients at risk of developing anemia could allow evaluation of suitability for therapy, and aid in determining frequency of anemia monitoring and treatment manageme...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jhep.2014.01.013

データ提供：米国国立医学図書館（NLM）

Telaprevir-Based Therapy: Navigating the Challenges of Anemia

Hepatitis C treatment is a complex journey, often accompanied by unexpected obstacles. This study, published in [Journal Name], investigates anemia, a common adverse event associated with telaprevir-based triple therapy for chronic, genotype 1 hepatitis C. It's like encountering a sandstorm during a desert trek, presenting a challenge that requires careful navigation. The researchers sought to identify risk factors predictive of anemia development during telaprevir therapy, aiming to improve patient management and outcomes. They believe that identifying high-risk patients could allow for better monitoring and tailored treatment approaches. It's like identifying potential hazards in the desert landscape to ensure a smoother and safer journey.

Anemia in Telaprevir Therapy: A Potential Pitfall

This study highlights the importance of careful monitoring and proactive management for patients undergoing telaprevir-based therapy. It's like having a compass and map to navigate the desert, ensuring that potential challenges are addressed promptly and effectively. The study suggests that early identification and intervention could help mitigate the risks associated with anemia development, improving patient well-being and treatment outcomes.

Navigating the Desert of Hepatitis C Treatment

This research underscores the importance of personalized care in managing hepatitis C. It's like having a knowledgeable guide to lead you through the complex desert landscape, ensuring that you have the right tools and resources for a successful journey.

Dr.Camel's Conclusion

This study sheds light on the complex interplay of telaprevir therapy and anemia development. It's a reminder that even in the face of challenging conditions, careful monitoring, and tailored interventions can lead to better outcomes. It's like navigating a desert landscape, where understanding the terrain and potential hazards allows for a smoother and more successful journey.

Date :
  1. Date Completed 2015-01-06
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

24486089

DOI: Digital Object Identifier

10.1016/j.jhep.2014.01.013

Related Literature

Article Analysis
・Effective treatment of anemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.